Frontiers reaches 6.4 on Journal Impact Factors

Correction ARTICLE

Front. Med., 24 January 2018 | https://doi.org/10.3389/fmed.2017.00257

Corrigendum: Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece

imageArgyrios Tzouvelekis1,2*†‡, imageTheodoros Karampitsakos3†, imagePaschalis Ntolios4, imageVasilios Tzilas1, imageEvangelos Bouros1, imageEvangelos Markozannes1, imageIoanna Malliou1, imageAris Anagnostopoulos1, imageAndreas Granitsas1, imagePaschalis Steiropoulos2, imageKaterina Dimakou3, imageSerafeim Chrysikos4, imageNikolaos Koulouris1 and imageDemosthenes Bouros1‡
  • 1First Academic Department of Pneumonology, Hospital for Diseases of the Chest “Sotiria”, Medical School, National and Kapodistrian University of Athens, Athens, Greece
  • 2Division of Immunology, Biomedical Sciences Research Center “Alexander Fleming”, Athens, Greece
  • 35th Respiratory Department, Hospital for Diseases of the Chest “Sotiria”, Athens, Greece
  • 4Department of Pneumonology, University Hospital of Alexandroupolis, Democritus University of Thrace, Komotini, Greece

A corrigendum on

Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
by Tzouvelekis A, Karampitsakos T, Ntolios P, Tzilas V, Bouros E, Markozannes E, et al. Front Med (2017) 4:213. doi: 10.3389/fmed.2017.00213

In the original article, there was a mistake in Figure 1 as published [x and y axes were mislabeled and ⋆p-value <0.05 indicating significance was missing]. The corrected Figure 1 appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

FIGURE 1
www.frontiersin.org

Figure 1. Changes in %forced vital capacity (ΔFVC) as %predicted ± SD, at different time points following pirfenidone treatment. Time 0 denotes the onset of treatment. Deaths were treated as censored. One-way ANOVA, p < 0.05.

In the original article, there was a mistake in Figure 2 as published [x and y axes were mislabeled and ⋆p-value <0.05 indicating significance was missing]. The corrected Figure 2 appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

FIGURE 2
www.frontiersin.org

Figure 2. Changes in %diffusion capacity of lung for carbon monoxide (ΔDLCO) as %predicted ± SD, at different time points following pirfenidone treatment. Time 0 denotes the onset of treatment. Deaths were treated as censored. One-way ANOVA, p < 0.05.

The original article was updated.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Keywords: pirfenidone, safety, efficacy, idiopathic pulmonary fibrosis, treatment

Citation: Tzouvelekis A, Karampitsakos T, Ntolios P, Tzilas V, Bouros E, Markozannes E, Malliou I, Anagnostopoulos A, Granitsas A, Steiropoulos P, Dimakou K, Chrysikos S, Koulouris N and Bouros D (2018) Corrigendum: Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece. Front. Med. 4:257. doi: 10.3389/fmed.2017.00257

Received: 06 December 2017; Accepted: 22 December 2017;
Published: 24 January 2018

Edited and Reviewed by: Mehdi Mirsaeidi, University of Miami, United States

Copyright: © 2018 Tzouvelekis, Karampitsakos, Ntolios, Tzilas, Bouros, Markozannes, Malliou, Anagnostopoulos, Granitsas, Steiropoulos, Dimakou, Chrysikos, Koulouris and Bouros. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Argyrios Tzouvelekis, argyrios.tzouvelekis@fleming.gr

These authors have contributed equally to this work.

These authors jointly supervised the work.